← Back to list
MA08.186a, Penpulimab-kcqx
Act
by May 31, 2026
Effective date
Jun 1, 2026
Identified
Jun 19, 2026
Summary
Independence Blue Cross Medicare Advantage policy MA08.186b expands coverage for penpulimab-kcqx to include three new cancer indications (anal carcinoma, appendiceal cancers, and small bowel adenocarcinoma) effective June 1, 2026, and revises head and neck cancer criteria per FDA and NCCN guidelines. Billing teams must add 13 new ICD-10 diagnosis codes and update prior authorization and coverage criteria in billing systems.
Get alerts when payers change rules like this one
We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.
Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.
What to do
by May 31, 2026 · 6 steps
01Billing and prior authorization teams must complete the following.
02Update billing system and prior authorization software to recognize new ICD-10 codes C17.0-C17.9, C18.1, C21.0-C21.2, C21.8, C31.0-C31.1, and D37.3 as covered indications for penpulimab-kcqx (billed as C9399 or J3590).
03Configure authorization rules to enforce new medical necessity criteria for anal carcinoma (combination therapy or single-agent second-line), appendiceal cancers (dMMR/MSI-H or POLE/POLD1 mutation with no prior checkpoint inhibitor), and revised nasopharyngeal carcinoma staging requirements (T1-4, N0-3, M1 with specific ECOG performance status).
04Update clinical staff encounter templates and prior authorization request forms to include required clinical documentation for performance status, prior treatments, and tumor genetics where applicable.
05Alert providers that claims for penpulimab-kcqx submitted without meeting the specified medical necessity criteria will be denied retroactively.
06Begin implementation immediately to allow testing before June 1, 2026 effective date.
Codes mentioned
C9399J3590C17.0C17.1C17.2C17.3C17.8C17.9C18.1C21.0C21.1C21.2C21.8C31.0C31.1D37.3C11.0C11.1C11.2C11.3C11.8C11.9C14.0C14.2
Original notice
MA08.186a, Penpulimab-kcqx
medpolicy.ibx.com · Always check the source before changing claims.
Related changes
See all Independence Blue Cross changes →08.02.42b, Penpulimab-kcqxLowEffective Oct 1, 2026 · Pharmacy08.02.42a, Penpulimab-kcqxMediumEffective Jun 1, 2026 · PharmacyMA08.186, Penpulimab-kcqxMediumEffective Dec 29, 2025 · Pharmacy08.02.42, Penpulimab-kcqxMediumEffective Dec 29, 2025 · PharmacyBrowse every Independence Blue Cross change in the policy list